

## **Mission Statement for the ATC Council of Industry Participants**

The mission of the ATC Council of Industry Participants (ACIP) is to interface with the Advanced Technology QA Consortium (ATC) in order to promote the development of a clinical trials informatics infrastructure that facilitates and supports volumetric digital data submission, data archiving, and remote web-based QA review for clinical trials that utilize advanced technologies. These advanced technologies include, but are not limited to, three-dimensional conformal radiation therapy (3DCRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic radiosurgery (SRS), and stereotactic body radiation therapy (SBRT), particle, and brachytherapy.

The ATC's vision is to promote the use of advanced medical informatics to facilitate digital data collection, information management, clinical trials QA remote review, and clinical trials education/training efforts, by providing an environment in which QA Centers and Cooperative Groups can receive, share, and analyze volumetric multimodality imaging, treatment planning, and verification (ITPV) digital data. The ATC's ultimate goal is to improve the standards of care in the management of cancer by improving the quality of clinical trials medicine.

The ATC informatics development effort has embraced a modular architecture philosophy with emphasis on well-defined interfaces and promotion of commercial "off-the-shelf" and open-source software products. Custom software component development is encouraged on only those QA features required, but not otherwise available commercially. By limiting the scope of module functions and using standards-based interfaces, maintenance/testing of new system components are also facilitated.

The ACIP will assist the ATC in realizing its vision and achieving its goals by (1) providing input regarding the latest informatics technology commercially available, and (2) periodically reviewing and assessing the ATC's informatics infrastructure and developmental schedule. It will provide a written report documenting findings and recommendations to the ATC on a yearly basis.

### **Members - ATC Council of Industry Participants**

Joel Goldwein, M.D., – Elekta IMPAC (Chair)

Mike Courtney – Philips

Damien Evans – TeraMedica

Sam Jeswani – TomoTherapy

Armin Langenegger, M.S. – Varian

Al Lawson, Ph.D. – CMS

jgoldwein@impac.com

mike.courtney@philips.com

devans@teramedica.com

sjeswani@tomotherapy.com

Armin.Langenegger@varian.com

Alfred.Lawson@cmsrtp.com